Rispetril 2mg 60 tablets — Made in Canada — Free Delivery

Brand: Pharmascience
Product Code: Rispetril 2mg
Availability: In Stock

$20.72

Add to Cart

Description

Product description

Rispetril tablets are indicated for:

treatment of schizophrenia and other mental disorders, including maintenance therapy in patients who have responded to therapy, in order to prevent relapse of the disease;
treatment of manic episodes in bipolar disorders (auxiliary therapy in combination with mood stabilizers as initial treatment or as monotherapy for up to 12 weeks);
short-term treatment of severe aggression or severe mental symptoms in patients with dementia when there is a threat of harm to themselves or others;
symptomatic treatment of defiant oppositional disorders or other disorders of social behavior in children, adolescents and adults with below average mental development or mental retardation who have manifestations of destructive behavior (impulsivity, auto-aggression);
symptomatic treatment of autistic disorders in children aged 5 years and over whose symptoms range from hyperactivity to irritability (including aggression, self-injury, anxiety, and pathological cycling).

Compound

One tablet contains risperidone 2 mg.

Excipients: lactose, sodium lauryl sulfate, microcrystalline cellulose, corn starch, magnesium stearate, colloidal silicon dioxide; shell: polyvinyl alcohol, macrogol, titanium dioxide (E 171), talc, sunset yellow FCF (E 110).

Contraindications

Hypersensitivity to the active ingredient or to any excipient in the formulation.

Mode of application

Usual dose: the preparation can be used once or twice a day, doses over 8 mg should be divided into two doses (morning and evening).

Schizophrenia (adults under age 65)

The preparation can be administered once or twice a day. You should start taking 2 mg of the preparation per day, on the second day the dose can be increased to 4 mg. Thereafter, the dose can be maintained unchanged or, if necessary, adjusted individually. For most patients, the recommended dose is 4-6 mg per day. Some patients may need to gradually increase the dose or reduce the initial dose. The maximum daily dose is 10 mg. Doses above 10 mg per day have not been found to be highly effective compared to lower doses, but they may cause extrapyramidal symptoms. Since the safety of doses exceeding 16 mg per day has not been studied, doses above this level should not be used.

Schizophrenia (elderly patients - over 65 years old)

The recommended starting dose is 0.5 mg twice daily. If necessary, the dose can be increased to 1-2 mg twice a day by increasing by 0.5 mg twice a day. If additional sedation is needed, a benzodiazepine may be used concomitantly.

Manic episodes in bipolar disorder (children over 10 years of age and adults)

The recommended starting dose is 2 mg once a day, in the evening. The dose can be individually increased by adding one mg/day no more than every 24 hours. The recommended dose range is 2 to 6 mg per day. As with other types of symptomatic treatment, with long-term use of this preparation, it is necessary to periodically review the doses and adjust them throughout therapy. There are no data on the effectiveness of the preparation in the treatment of acute bipolar mania lasting more than 12 weeks. If "Rispetril" is used in combination with normothymics, therapy can be stopped earlier, since the onset of the effect of treatment can be expected in the first weeks of therapy. Even after the first response to treatment, the possibility of recurrence of symptoms of depression should be considered due to the nature of the course of the disease and the adverse reactions of the preparations that were used for treatment, including this preparation.

Short-term therapy for severe aggression or severe psychiatric symptoms in patients with dementia

The recommended starting dose is 0.25 mg twice daily. If necessary, the dose can be increased by increasing the dose by 0.25 mg twice a day no more than every other day. For most patients, the optimal dose is 0.5 mg twice daily. However, for some patients, the effective dose can be increased to one mg twice a day. Once the optimal dose has been reached, a once-daily daily dose may be considered. Cancellation of treatment with this preparation should take place no later than three months after the start of therapy, therapy can only be resumed if behavioral disorders reappear.

Symptomatic treatment of social behavior disorders or aggressive behavior (patients weighing > 50 kg)

The recommended starting dose is 0.5 mg once daily. If necessary, the dose should be adjusted by adding 0.5 mg once a day no more than every other day. The optimal dose for most patients is 1 mg once daily. However, for some patients, no more than 0.5 mg once a day is sufficient to achieve a positive effect, while others may require 1.5 mg once a day.

Symptomatic treatment of disorders of social behavior or aggressive behavior (patients weighing < 50 kg - children from 5 years and adults)

The recommended starting dose is 0.25 mg once daily. If necessary, the dose can be adjusted by adding 0.25 mg once a day no more than every other day. The optimal dose for most patients is 0.5 mg once daily. However, for some patients, no more than 0.25 mg once a day is sufficient to achieve a positive effect, while others may require 0.75 mg once a day. As with other symptomatic treatments, long-term use of this preparation should be periodically reviewed and adjusted throughout therapy.

Autism

Children from 5 years of age: the dose should be selected individually, depending on the patient's condition and clinical response.

Patients weighing < 50 kg: The recommended starting dose is 0.25 mg once daily; from the fourth day the dose can be increased by 0.25 mg; a dose of 0.5 mg should be maintained and clinical response assessed on day 14; dose increases of 0.25 mg at two-week intervals should only be considered in patients with poor clinical response.

Patients weighing ≥ 50 kg: the recommended initial dose is 0.5 mg once a day; from the fourth day the dose can be increased by 0.5 mg; a dose of 1 mg should be maintained and clinical response assessed on day 14; dose increases of 0.5 mg at two-week intervals should only be considered in patients with poor clinical response.

Application features

pregnant

"Rispetril" is not recommended for use during pregnancy, except in cases of vital necessity. If you need to stop treatment with this preparation during pregnancy, do not do it suddenly.

Risperidone and 9-hydroxyrisperidone have been excreted into breast milk in animal studies. There are observations that risperidone and 9-hydroxyrisperidone may also be excreted in breast milk in small amounts. In some cases, 4.3% of the dose that the mother used in the form of an active antipsychotic fraction of the active substance was determined in breast milk. If necessary, breastfeeding should be discontinued.

Children

The preparation is used for the symptomatic treatment of exclusively social behavior disorders, defiant oppositional disorders or other social behavior disorders, as well as autistic behavioral disorders in children aged 5 years and older.

Drivers

The preparation may have a slight or moderate effect on the ability to drive vehicles due to potential effects on the nervous system and organs of vision. During treatment, it is recommended to refrain from driving vehicles or working with mechanisms until the individual sensitivity of patients to the preparation becomes known.

Overdose

Symptoms

The signs and symptoms of overdose that have been observed are the known adverse reactions of the preparation in an enhanced form: drowsiness and sedation, tachycardia and arterial hypotension, as well as extrapyramidal symptoms. In case of overdose, QT prolongation and convulsions have been reported. Flutter-flicker has been reported associated with an overdose of risperidone in combination with paroxetine. In case of acute overdose, the possibility of interaction of several preparations should be analyzed.

Treatment

An open airway should be established and maintained to ensure adequate ventilation and oxygenation. Gastric lavage (after intubation if the patient is unconscious) and administration of activated charcoal along with a laxative should be considered no later than one hour after taking the preparation. Cardiovascular monitoring is indicated, including continuous ECG recording to detect possible arrhythmias. The preparation has no specific antidote. Therefore, appropriate supportive measures should be taken. Arterial hypotension and circulatory collapse should be treated with measures such as intravenous fluids and/or sympathomimetic preparations. If acute extrapyramidal symptoms develop, anticholinergic preparations should be prescribed. Continuous medical supervision and monitoring should continue until the patient recovers.

Side effects

The most commonly reported adverse reactions are parkinsonism, headache and insomnia.

Storage conditions

Store in the original packaging at a temperature not exceeding 25°C, out of the reach of children.

Shelf life - 5 years.

0 reviews

There are no reviews for this product.